can you drink caffeine on semaglutide Does Ozempic Have Caffeine? Facts About Ingredients Debunking the Myth: Iced Coffee

The Wellness Center of Greater Cleveland team of healthcare professionals is available to help guide you through the process and ensure your success in achieving long-term weight loss goals

incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4,825 participants (13.8%

Judicial Panel for Multidistrict Litigation (JPML) formed another GLP-1 MDL, transferring cases involving claims of NAION (non-arteritic anterior ischemic optic neuropathy) to an MDL named In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL 3163

Psychologically, the stress of dieting and the pressure to lose weight can make it challenging to stick to your plan

FDA-Approved Brand-Name Medications : According to FDA definitions and regulatory framework: Characteristics : Undergone rigorous FDA review process including: Preclinical studies (animal testing) Phase 1 trials (safety in small human groups) Phase 2 trials (efficacy in moderate human groups) Phase 3 trials (large-scale efficacy and safety) FDA review of manufacturing, labeling, marketing Manufacturing in FDA-inspected facilities with strict quality controls Consistent potency, purity, and sterility guaranteed Extensive safety and efficacy data available Post-marketing surveillance for ongoing safety monitoring Clear prescribing information and contraindications Available FDA-Approved GLP-1 Weight Loss Medications : Wegovy (semaglutide 2.4 mg) - Approved June 2021 Zepbound (tirzepatide) - Approved November 2023 Saxenda (liraglutide 3.0 mg) - Approved December 2014 Advantages : Proven safety and efficacy through clinical trials Consistent quality and potency FDA oversight and accountability Insurance coverage possibility (if approved) Comprehensive prescribing information Manufacturer support programs Disadvantages : Higher cost (typically $1,000-$1,400/month retail) Insurance coverage inconsistent Supply shortages have occurred Compounded GLP-1 Medications : According to FDA guidance on compounding: Characteristics : Custom-prepared by compounding pharmacies Not FDA-approved (have not undergone FDA review process) Made under state pharmacy board oversight (not FDA) May vary in formulation, strength, or delivery method from FDA-approved versions Limited quality control compared to FDA-approved drugs No clinical trial data specific to compounded formulation Safety and efficacy not independently verified Regulatory Framework : Legal under certain circumstances per Drug Quality and Security Act Compound pharmacies must be registered with state boards Cannot compound exact copies of FDA-approved drugs (must differ in some way) During drug shortages, FDA may allow compounding of shortage drugs FDA has enforcement discretion but limited direct oversight Advantages : Lower cost (typically $199-$499/month depending on platform) Faster access (no insurance authorization delays) May be available when brand-name shortage occurs Some platforms offer additional formulations (oral, sublingual) Disadvantages : Not FDA-approved (no FDA safety/efficacy review) Quality and consistency may vary between pharmacies Potency not guaranteed to match clinical trial medications No manufacturer support or savings programs Cannot use insurance (cash-pay only) Limited recourse if problems occur FDA Warning on Compounded GLP-1s : According to FDA statements published in 2024-2025: FDA has warned about compounded GLP-1 medications Concerns include: Dosing errors reported Contamination incidents Ineffective products (insufficient active ingredient) Counterfeit products claiming to be compounded FDA recommends patients use FDA-approved versions when possible Compounded Medication Disclosure: Clinical trial data demonstrating 15-20% weight loss was conducted using FDA-approved medications

Ethics declarations Competing Interest The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper